Oral Semaglutide
OASIS 1
Novo Nordisk · Phase 3 · Completed · Enrollment 667
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Oral semaglutide | Obesity or overweight | n/r | 1 | n/r | n/r |
| Oral semaglutide placebo | Obesity or overweight | n/r | 1 | n/r | n/r |
Disease Pipeline Tools Obesity
Obesity
Programs, trials, and reported weight change for obesity and overweight.
Oral Semaglutide
Novo Nordisk · Phase 3 · Completed · Enrollment 667
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Oral semaglutide | Obesity or overweight | n/r | 1 | n/r | n/r |
| Oral semaglutide placebo | Obesity or overweight | n/r | 1 | n/r | n/r |